Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kuznetsova A, Gorbunova V, Orel N, Emelianova G, Markovich A,

Keywords: lung neuroendocrine tumors, Everolimus,

#1338 Use of Lanreotide LAR in the Case of Intolerance of Octreotide LAR in Patients Well-differentiated NETs

Introduction: Intolerance of Octreotide is about 10 % of cases

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Emelianova G, Kuzminov A, Markovich A,

Keywords: Octreotide, Lanreotide, intolerance, NETs,

#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Emelianova G, Odintsova A,

Keywords: aranoza, Neuroendocrine tumors, chemotherapy,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.